News

Pharmaceutical Technology1h
FDA accepts Novo Nordisk’s NDA submission for weight management therapy
The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...
Pharmabiz1h
US FDA accepts Novo Nordisk’s NDA submission for oral semaglutide 25 mg for treatment of obesity
Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...
News-Medical.Net8h
Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows
A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...